Hancock Whitney’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.2M Buy
+120,045
New +$7.56M 0.13% 150
2024
Q2
– Sell
-2,398
Closed -$209K – 610
2024
Q1
$209K Hold
2,398
– – 0.01% 612
2023
Q4
$231K Hold
2,398
– – 0.01% 595
2023
Q3
$212K Hold
2,398
– – 0.01% 587
2023
Q2
$208K Sell
2,398
-132
-5% -$12.4K 0.01% 595
2023
Q1
$246K Buy
2,530
+20
+0.8% +$2.07K 0.01% 575
2022
Q4
$260K Hold
2,510
– – 0.01% 560
2022
Q3
$213K Hold
2,510
– – 0.01% 581
2022
Q2
$208K Buy
+2,510
New +$200K 0.01% 608
2022
Q1
– Sell
-2,510
Closed -$222K – 690
2021
Q4
$222K Sell
2,510
-80
-3% -$6.6K 0.01% 649
2021
Q3
$200K Sell
2,590
-458
-15% -$36.1K 0.01% 652
2021
Q2
$254K Buy
3,048
+69
+2% +$5.47K 0.01% 717
2021
Q1
$225K Sell
2,979
-461
-13% -$37.7K 0.01% 716
2020
Q4
$302K Sell
3,440
-208
-6% -$16.5K 0.01% 642
2020
Q3
$278K Sell
3,648
-72
-2% -$7.28K 0.01% 647
2020
Q2
$459K Sell
3,720
-307
-8% -$30.5K 0.02% 527
2020
Q1
$340K Buy
4,027
+92
+2% +$7.93K 0.01% 600
2019
Q4
$333K Sell
3,935
-899
-19% -$67.9K 0.01% 657
2019
Q3
$326K Sell
4,834
-146
-3% -$11.2K 0.01% 676
2019
Q2
$427K Sell
4,980
-116
-2% -$9.9K 0.01% 650
2019
Q1
$453K Sell
5,096
-1,357
-21% -$126K 0.01% 643
2018
Q4
$549K Sell
6,453
-453
-7% -$43.1K 0.02% 545
2018
Q3
$670K Buy
+6,906
New +$689K 0.02% 575

Other funds holding BMRN

Hancock Whitney's BMRN Position: Q3 2026 in Review

Hancock Whitney opened a new position in BioMarin Pharmaceuticals (BMRN) in Q3 2026: 120,045 shares worth $7.2M. The stake represents 0.13% of the portfolio and ranks #150 among its holdings. This is a return to the name: Hancock Whitney previously reported a position in BMRN as recently as Q1 2024.

Hancock Whitney first reported a position in BMRN in Q3 2018 and has held it in 23 quarters since. 567 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

  • Hancock Whitney held 120,045 shares of BioMarin Pharmaceuticals worth $7.2M as of Q3 2026.
  • BioMarin Pharmaceuticals was a new Hancock Whitney position in Q3 2026.
  • BioMarin Pharmaceuticals made up 0.13% of Hancock Whitney's portfolio in Q3 2026, its #150 holding.
  • Hancock Whitney first reported a position in BioMarin Pharmaceuticals in Q3 2018 and has held it in 23 quarters since.
  • 567 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on Hancock Whitney's 13F filing for Q3 2026, filed 16 Nov 2026.